Optimal management of hormone receptor positive metastatic breast cancer in 2016

by Tomas Reinert, Carlos H. Barrios
Published 2015-11-01

Overall survival and progression-free survival with endocrine therapy for hormone receptor-positive, HER2-negative advanced breast cancer: review

by Tomás Reinert, Carlos H. Barrios
Published 2017-11-01

Tissue-agnostic drug approvals: how does this apply to patients with breast cancer?

by Luiza N. Weis, Sara M. Tolaney, Carlos H. Barrios, Romualdo Barroso-Sousa
Published 2021-09-01

Estimation of Premature Deaths From Lack of Access to Anti-HER2 Therapy for Advanced Breast Cancer in the Brazilian Public Health System

by Márcio Debiasi, Tomás Reinert, Rafael Kaliks, Gilberto Amorim, Maira Caleffi, Carlos Sampaio, Gustavo dos Santos Fernandes, Carlos H. Barrios
Published 2017-06-01

Molecular testing and treatment patterns for patients with advanced non-small cell lung cancer: PIvOTAL observational study.

by Dae Ho Lee, Ming-Sound Tsao, Karl-Otto Kambartel, Hiroshi Isobe, Ming-Shyan Huang, Carlos H Barrios, Adnan Khattak, Filippo de Marinis, Smita Kothari, Ashwini Arunachalam, Xiting Cao, Thomas Burke, Amparo Valladares, Javier de Castro
Published 2018-01-01

Cross-Cultural Validity Study of a Medical Education Leadership Competencies Instrument in Latin American Physicians: A Multinational Study

by Max S. Mano, Rafaela Gomes, Gustavo Werutsky, Carlos H. Barrios, Gustavo Nader Marta, Cynthia Villarreal-Garza, Antonio Luiz Frasson, Cinthya Sternberg, Renan Clara, Sergio D. Simon, Fadil Çitaku, Marianne Waldrop, Claudio Violato, Don Zillioux, Yawar Hayat Khan
Published 2019-11-01

Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positi...

by Edith A. Perez, Sanne Lysbet de Haas, Wolfgang Eiermann, Carlos H. Barrios, Masakazu Toi, Young-Hyuck Im, Pier Franco Conte, Miguel Martin, Tadeusz Pienkowski, Xavier B. Pivot, Howard A. Burris, Sven Stanzel, Monika Patre, Paul Anthony Ellis
Published 2019-06-01

Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced bre...

by Edith A. Perez, Sanne Lysbet de Haas, Wolfgang Eiermann, Carlos H. Barrios, Masakazu Toi, Young-Hyuck Im, Pier Franco Conte, Miguel Martin, Tadeusz Pienkowski, Xavier B. Pivot, Howard A. Burris, Sven Stanzel, Monika Patre, Paul Anthony Ellis
Published 2019-05-01

Stage III Non–Small-Cell Lung Cancer Treated With Concurrent Chemoradiation Followed or Not by Consolidation Chemotherapy: A Survival Analysis From a Brazilian Multicentric Cohort...

by Vladmir C. Cordeiro de Lima, Clarissa S. Baldotto, Carlos H. Barrios, Eldsamira M. Sobrinho, Mauro Zukin, Clarissa Mathias, Facundo Zaffaroni, Rodrigo C. Nery, Gabriel Madeira, Alex V. Amadio, Juliano C. Coelho, Guilherme Geib, Maria Fernanda Simões, Gilberto Castro Jr
Published 2018-05-01

ESR1 Mutations Are Not a Common Mechanism of Endocrine Resistance in Patients With Estrogen Receptor–Positive Breast Cancer Treated With Neoadjuvant Aromatase Inhibitor Therapy

by Tomás Reinert, Tomás Reinert, Tomás Reinert, Susana Ramalho, Vivian Castro Antunes de Vasconcelos, Leonardo Roberto Silva, Ana Elisa Ribeiro da Silva, Camila Annicchino de Andrade, Maria Beatriz de Paula Leite Kraft, Guilherme Portela Coelho, Jovana Mandelli, Monique Binotto, Cesar Cabello, Geisilene Russano de Paiva Silva, José Bines, Carlos H. Barrios, Matthew J. Ellis, Marcia Silveira Graudenz
Published 2020-04-01

Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer

by Francesco Schettini, Nuria Chic, Fara Brasó-Maristany, Laia Paré, Tomás Pascual, Benedetta Conte, Olga Martínez-Sáez, Barbara Adamo, Maria Vidal, Esther Barnadas, Aranzazu Fernández-Martinez, Blanca González-Farre, Esther Sanfeliu, Juan Miguel Cejalvo, Giuseppe Perrone, Giovanna Sabarese, Francesca Zalfa, Vicente Peg, Roberta Fasani, Patricia Villagrasa, Joaquín Gavilá, Carlos H. Barrios, Ana Lluch, Miguel Martín, Mariavittoria Locci, Sabino De Placido, Aleix Prat
Published 2021-01-01

PET-CT has low specificity for mediastinal staging of non-small-cell lung cancer in an endemic area for tuberculosis: a diagnostic test study (LACOG 0114)

by Gustavo Werutsky, Bruno Hochhegger, José Antônio Lopes de Figueiredo Pinto, Jeovany Martínez-Mesa, Mara Lise Zanini, Eduardo Herz Berdichevski, Eduardo Vilas, Vinícius Duval da Silva, Maria Teresa Ruiz Tsukazan, Arthur Vieira, Leandro Genehr Fritscher, Louise Hartmann, Marcos Alba, Guilherme Sartori, Cristina Matushita, Vanessa Bortolotto, Rayssa Ruszkowski do Amaral, Luís Carlos Anflor Junior, Facundo Zaffaroni, Carlos H. Barrios, Márcio Debiasi, Carlos Cezar Frietscher
Published 2019-01-01

PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial

by Stephen K. L. Chia, Miguel Martin, Frankie A. Holmes, Bent Ejlertsen, Suzette Delaloge, Beverly Moy, Hiroji Iwata, Gunter von Minckwitz, Janine Mansi, Carlos H. Barrios, Michael Gnant, Zorica Tomašević, Neelima Denduluri, Robert Šeparović, Sung-Bae Kim, Erik Hugger Jakobsen, Vernon Harvey, Nicholas Robert, John Smith, Graydon Harker, Bo Zhang, Lisa D. Eli, Yining Ye, Alshad S. Lalani, Marc Buyse, Arlene Chan
Published 2019-03-01